In the preceding three months, 6 analysts have released ratings for Moderna (NASDAQ:MRNA), presenting a wide array of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $119.17, a high estimate of $163.00, and a low estimate of $86.00. This upward trend is apparent, with the current average reflecting a 19.56% increase from the previous average price target of $99.67.

Interpreting Analyst Ratings: A Closer Look

The standing of Moderna among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Moderna's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Moderna analyst ratings.

Unveiling the Story Behind Moderna

Financial Insights: Moderna

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: Moderna's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -45.37%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Moderna's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 7.71%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Moderna's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.59%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Moderna's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.15%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Moderna's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.

How Are Analyst Ratings Determined?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.